PTC Therapeutics, Inc. (PTCT) Analysts See $-0.23 EPS

February 20, 2018 - By Henry Gaston

 PTC Therapeutics, Inc. (PTCT) Analysts See $ 0.23 EPS
Investors sentiment increased to 1.71 in Q3 2017. Its up 0.79, from 0.92 in 2017Q2. It increased, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported.
157,800 were accumulated by South Dakota Inv Council. Moreover, Fincl Bank Of Montreal Can has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). D E Shaw reported 0.07% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Canada Pension Plan Inv Board has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). State Board Of Administration Of Florida Retirement Sys has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Sei Invs has 1,115 shares for 0% of their portfolio. Blackrock holds 0% or 3.14 million shares. California Employees Retirement Systems owns 34,878 shares or 0% of their US portfolio. Art Lc accumulated 45,063 shares or 0.05% of the stock. J Goldman L P holds 28,180 shares. Janney Montgomery Scott Limited Liability Corp invested in 0.01% or 27,827 shares. Brandywine Investment Management Ltd Llc holds 1 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) reported 1,370 shares. Fmr Ltd Company stated it has 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). State Of Wisconsin Invest Board owns 24,000 shares.

Since January 3, 2018, it had 0 insider purchases, and 4 sales for $61,523 activity. Shares for $7,280 were sold by Utter Christine Marie. Another trade for 77 shares valued at $1,361 was sold by Almstead Neil Gregory.

Analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report $-0.23 EPS on March, 15.They anticipate $0.55 EPS change or 70.51 % from last quarter’s $-0.78 EPS. After having $-0.67 EPS previously, PTC Therapeutics, Inc.’s analysts see -65.67 % EPS growth. The stock decreased 2.37% or $0.58 during the last trading session, reaching $23.93. About 581,392 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since February 20, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 35 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Hold” rating given on Wednesday, February 24 by Jefferies. As per Monday, October 9, the company rating was downgraded by JP Morgan. The rating was downgraded by Bank of America to “Sell” on Thursday, October 26. The rating was upgraded by Citigroup to “Buy” on Friday, November 11. Oppenheimer maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) rating on Thursday, February 25. Oppenheimer has “Outperform” rating and $111 target. On Friday, June 30 the stock rating was maintained by Cowen & Co with “Hold”. RBC Capital Markets maintained the stock with “Hold” rating in Thursday, September 14 report. J.P. Morgan upgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Thursday, November 16 to “Hold” rating. Credit Suisse downgraded it to “Neutral” rating and $6 target in Tuesday, July 26 report. The company was initiated on Tuesday, August 25 by Citigroup.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $992.85 million. The company's lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

More recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “Form 8-K PTC THERAPEUTICS, INC. For: Jan 27” on January 29, 2018. Also published the news titled: “PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for …” on February 13, 2018.‘s news article titled: “PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare …” with publication date: February 09, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.